NCT07016321View on ClinicalTrials.gov

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 1, 2029

Study Completion Date

May 3, 2029

Conditions
Dengue
Interventions
DRUG

Emetine Hydrochloride 6mg

To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.

DRUG

Placebo

Participant take a placebo for 10 consecutive days.

DRUG

Emetine Hydrochloride 12mg

To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.

Trial Locations (2)

21231

Johns Hopkins University, Division of Infectious Disease, Baltimore

Unknown

Bharatpur Hospital, Bharatpur-10

All Listed Sponsors
collaborator

Bharatpur Hospital Chitwan

UNKNOWN

lead

Johns Hopkins University

OTHER

NCT07016321 - Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) | Biotech Hunter | Biotech Hunter